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ABSTRACT
Undifferentiated pleomorphic sarcoma (UPS) is a high-grade pleomorphic neoplasm with no identifiable line(s) of 
differentiation using currently available diagnostic techniques. Therefore, it is essentially a diagnosis of exclusion, which 
requires generous tissue sampling, adequate contextually interpreted immunohistochemistry, and relevant molecular 
studies. UPS is a common soft tissue sarcoma (historically one of the entities referred to as malignant fibrous histiocytoma 
(MFH)), which can develop in various organs, but lung involvement is usually due to metastasis. Primary Pulmonary 
UPS (PPUPS) is exceptionally rare and here we present a 66-year-old man who presented with anemia and weight 
loss, found to have a 17 cm right lung mass with invasion to the chest wall and diaphragm. Extensive sampling and 
immunohistochemistry studies failed to reveal any line of differentiation. Upon exclusion of a possible extrapulmonary 
origin, a diagnosis of PPUPS was rendered. In addition, we reviewed all 84 previously reported cases of PPUPS/PPMFH in 
the literature since 1979 and summarized the clinical information. 
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INTRODUCTION
Undifferentiated pleomorphic sarcomas (UPS), 
one of the entities previously included in the effete 
diagnosis of malignant fibrous histiocytoma (MFH), 
most commonly occurs in deep soft tissue of extremities 
(thigh) of elderly patients (average 50-70 years). So-called 
MFH was in the past thought to be of fibrohistiocytic 
origin; however, further studies (electron microscopy, 
immunohistochemical techniques, or molecular studies) 
failed to demonstrate evidence of “fibrohistiocytic” 
differentiation. Additionally, other unrelated poorly 
differentiated sarcoma was included in this entity, 
compounding the non-specific and confusing nature 
of this diagnostic term. MFH was declassified by 
World Health Organization (WHO) in 2012, and is 
no longer listed as a diagnostic entity. Many tumors 
previously included as MFH have been reclassified as 
“undifferentiated pleomorphic sarcoma”. 1
Primary sarcomas in lung are rare (less than 
0.5% of all lung cancers)2, and primary pulmonary 
undifferentiated pleomorphic sarcomas (PPUPS) are 
one of the least common primary lung sarcomas, 
with 84 reported cases in the English literature 
(Table 1). Weiss SW and Enzinger FM first described 
soft tissue MFH of 200 cases in 1978.3 A year later, 
Bedrossian et al.4 reported the first case of primary 
pulmonary MFH (PPMFH) in a 51-year-old man.
Yousem and Hochholzer5 reported the most 
extensive series of primary malignant f ibrous 
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histiocytomas in the lung in 1987 with 22 cases (patient 
age range of 18 to 80 years). Previous irradiation is 
a known pathogenic risk factor for soft tissue UPS. 
Similarly, few reports are available in the literature 
regarding patients who develop PPUPS years after 
radiation therapy for another tumor.6,7 It is unclear 
whether de-novo PPUPS and radiation associated 
undifferentiated pleomorphic sarcomas represent the 
same entity.
Clinical presentations in pulmonary tumors, as 
with other types of lung cancers, depends more on 
the tumor location rather than the histological type. 
Primary pulmonary sarcomas often present as a large 
peripheral or hilar well-circumscribed mass, and may 
present as an endobronchial tumor in 10% of cases.8 
The majority of patients present with symptoms of 
cough, chest pain, hemoptysis, or dyspnea. Radiologic 
findings can show a solitary mass with or without 
post-obstructive effects (recurrent pneumonia, 
bronchiectasis, lobar or segmental atelectasis), and 
in some cases with extraluminal growth and/or local 
invasion into adjacent structures.1
Table 1. Helpful ancillary tests to differentiate tumors with sarcomatoid features
Tumor Immunohistochemistry Molecular
Sarcomatoid Carcinoma (SC)
P63+, P40+, PanKeratin+, TTF1+, 
epithelial markers (MOC31, BerEP4, 
BG8, B72.3, monoclonal CEA)+
Gains at chromosomes 8q, 7, 1q, 3q, 
and 19.
KRAS mutation, EGFR mutation
Sarcomatoid Mesothelioma WT1+, CK5/6+, D2-40+, calretinin+ Inactivation of CDKN2A at 9p21 on PCR
Angiomatoid fibrous histiocytoma 
(AFH) Desmin+/-, CD68+/-, EMA+/-
EWSR1-CREB1, EWSR1-ATF1, or 
FUS-ATF1 fusion
Synovial sarcoma (SS) TLE1+, Keratin+, EMA+, S100+/-, CD56+, CD99+, Calretinin+/- t(X;18) involving SS18 (SYT) gene
Epithelioid Sarcoma (ES) Loss INI, EMA+, Keratin+/-, CD34+/- SMARCB1 (INI1) gene alterations on (22q11)
Dedifferentiated liposarcoma (DDLPS) MDM2+, CDK4+, SMA+/-, Desmin+/-
Ring and giant marker chromosomes 
derived from amplification of 
12q13–15 (variable amplification of 
MDM2, SAS, CDK4, HMGA2)
Anaplastic large-cell lymphoma (ALCL) CD45+, CD30+, ALK+/- TCR gene rearrangement, Rearrangement of 2p23 (ALK)
Inflammatory myofibroblastic tumor 
(IMT) ALK+/-, SMA+/-, Desmin+/- Rearrangement of 2p23 (ALK)
Ewing Sarcoma FLI1+, CD99+ t(11;22) and other translocations involving EWSR1 gene
Melanoma S100+, SOX10+, MelanA/MART1+, MITF+, Tyrosinase+
BRAF, ARID2, BAP1, GNAQ, HRAS, 
KIT, NF1, NRAS, and PTEN mutations
Malignant peripheral nerve sheath 
tumors (MPNST) S100+/-, GFAP+/-. CD34+/- Complex
Solitary fibrous tumor (SFT) STAT6+, CD34+, BCL2+ NAB2-STAT6 fusion
Leiomyosarcoma (LMS) SMA+, Desmin+, Caldesmon+ Complex
Rhabdomyosarcoma (RMS) Desmin+, Myogenin+, MyoD1+ Complex
Angiosarcoma
Vascular markers (CD31, CD34, FLI1, 
ERG)+, Keratin +/- in epithelioid 
angiosarcoma
MYC (8q24) or FLT4 (VEGFR3) 
(5q35) amplification, Upregulation 
of vascular-specific receptor tyrosine 
kinases (TIE1, KDR, TEK, FLT1)
Kaposi Sarcoma
HHV8 (LANA)+, vascular markers+, 
Lymphatic markers (D2-40, LYVE1, 
Prox1)+
KSHV/HHV8 with PCR
Epithelioid hemangioendothelioma 
(EHE) Vascular markers+, TFE3+/-, Keratin +/-
WWTr1-CAMTA1 fusion, YAP1-TFE1 
fusion
Alveolar soft part sarcoma (ASPS) TFE3+, Desmin+/- der(17)t(X;17)(p11.2;q25) translocation (ASPSCR1-TFE3 fusion)
Perivascular epithelioid cell tumor 
(PEComa)
SMA+, Desmin+, HMB45+, MITF+, 
MART1+ TSC2 mutations, TFE3 gene fusions
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Since clinical and radiographic features of these 
tumors are nonspecific, pathological tissue examination 
is required to differentiate them from the much more 
common epithelial tumors of the lung. The clinical 
course of these tumors is generally rapidly progressive 
and metastasis is common.4 The majority of patients 
die within a period of 1 to 72 months. Endobronchial 
masses showed more favorable prognosis compare to 
other origins.8
Here we report the only case of PPUPS that was 
diagnosed at UCLA from 2002 to 2019.
CASE REPORT
A 66-year-old man who presented with right sided 
chest wall pain, weight loss (7 kg), fatigue, and night 
sweats, without any significant past medical history, 
was found to have normocytic anemia and a large right 
inferior hemithorax mass on chest X-ray, which was 
inseparable from the right hemidiaphragm (Figure 1).
Computed tomography (CT) scan showed a 
large (15 × 13.6 × 6.2 cm), poorly circumscribed, 
heterogeneous mass within the right base of the lung 
involving the pleural surface and mildly protruding 
into the 8th and 9th intercostal spaces, without eroding 
of the adjacent bones (Figure 2). Positron emission 
tomography–computed tomography (PET-CT) scan 
revealed a large right inferior hemithorax mass with 
intense fluorodeoxyglucose (FDG) uptake (standardized 
uptake values (SUVs) of 22.3). The mass abutted 
the right hemidiaphragm and the chest wall with 
suggestion of extension into the rib interspaces, most 
prominent at the right 8th rib interspace. A 6.1 cm 
right superior paramediastinal mass with intense FDG 
uptake (SUVMax 16.3) was also seen, suspicious for 
pleural deposit/metastatic disease (Figure 2).
A CT guided core biopsy was subsequently 
performed. Histological examination revealed a poorly 
differentiated malignant neoplasm with epithelioid 
morphology (Figure 3). Microscopic examination did 
not reveal any line of differentiation by morphology 
or upon application of immunohistochemistry; tumoral 
cells were negative for TTF-1, epithelial (pankeratin, 
EMA, CAM5.2), mesothelial (calretinin), melanocytic 
(S100 protein, SOX10, MART1), vascular (CD34), and 
myogenic (desmin, caldesmon) markers. Therefore, the 
favored diagnosis was poorly differentiated malignant 
epithelioid neoplasm.
Figure 1. Chest X-Ray (A) anteroposterior view; 
(B) lateral view showing a large right lower lung mass.
Figure 2. Imaging study of the thorax. CT scan (A - axial 
plane, C - coronal plane) shows a 15 × 6 cm poorly 
circumscribed right lower lung mass protruding into 
the 8th and 9th intercostal spaces. (B - axial plane and 
D - coronal plane) PET scan shows a 15 cm right inferior 
lung mass and a 6 cm right superior paramediastinal 
mass with high FDG uptake.
Figure 3. Photomicrograph of the CT-Guided biopsy 
showed a poorly differentiated malignant epithelioid 
neoplasm (H&E, 10X).
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Subsequently, the patient underwent surgical 
wedge resection of right lower and middle lobes, along 
with the adjacent right chest wall. Gross examination 
showed a well-circumscribed light tan and firm mass 
with areas of necrosis and hemorrhage, which abutted 
Figure 4. Gross examination of the lung mass resection.
Figure 5. Photomicrographs of the tumor showing in A – Vaguely nodular high-grade spindle to epithelioid 
neoplasm with adjacent rib bone (H&E, 3X); B – Neoplastic cells with adjacent normal lung parenchyma (H&E, 
14X); C – Undifferentiated pleomorphic sarcoma with areas of necrosis (H&E, 10X); D – Pleomorphic cells with high 
mitotic activity, atypical mitoses, chronic inflammatory cell infiltrate and focal necrosis (H&E, 12.5X).
the bone without any gross or microscopic evidence of 
invasion. The mass measured 17.5 cm × 6.5 cm × 1.5 cm 
(Figure 4).
Representative sections showed a vaguely nodular 
mass consists of spindle to epithelioid neoplastic cells 
arranged in sheets and fascicles some in a storiform 
pattern. Large, bizarre pleomorphic cells with round to 
oval nuclei, prominent nucleoli, and moderate amounts 
of cytoplasm were observed (Figure 5A and 5B). 
Areas of necrosis (Figure 5C) and high mitotic activity, 
including atypical mitosis (Figure 5D), were identified.
All surgical margins were free of malignancy and 
no lymph node metastasis was identified. As with 
the biopsy, the neoplastic cells did not show any 
immunoreactivity to epithelial, mesothelial, or glandular 
markers; negative staining for pankeratin, CAM5.2, 
Keratin 5/6, p63, calretinin, WT1, D2-40, TTF1, S100, 
SOX10, MART1, HMB45, desmin, caldesmon, EMA, 
CD34, STAT6, C-Kit, DOG1, myogenin, MyoD1, CD21, 
CD23, CD35, chromogranin, TLE1, BCL2, and CD99 
(Figure 6). Since no evidence of extrapulmonary origin 
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was identified and the tumor did not demonstrate 
any line of differentiation in our extensive work up, 
the diagnosis of primary pulmonary undifferentiated 
pleomorphic sarcoma (PPUPS) was rendered.
Final Pathologic Diagnosis: (i) Undifferentiated 
pleomorphic sarcoma, high grade, 17.5 cm; (ii) Surgical 
margins are uninvolved.
The patient was further treated with radiotherapy 
and multiple cycles of adjuvant chemotherapy (7 days 
cycle per month with Ifosfamide 1500mg/m2 CIV on 
days 1-7). Patient tolerated the treatment without any 
evidence of local recurrence or metastasis up to this 
date (4 months follow up).
DISCUSSION
Primary lung sarcomas are rare, and represents 
less than 0.5% of lung malignancies. Cameron9 and 
Miller and Allen10 reported primary lung sarcomas 
in 0.15% and 0.3% of lung neoplasms in studies of 
6000 and 10134 patients with primary lung malignancies 
respectively. Among the primary pulmonary sarcomas, 
undifferentiated pleomorphic sarcoma (UPS) is one of 
the rarest one with less than 84 reported cases. UPS is 
defined as a high-grade pleomorphic neoplasm that 
shows no discernible microscopic evidence of any 
specific form of differentiation (e.g., lipoblasts, bone 
formation, epithelial structures) using currently available 
diagnostic techniques. Fletcher CD in a retrospective 
study on re-analysis of 159 tumors showed that 
just 26% of previously diagnosed MFH cases were 
“true” UPSs, and more than half of cases showed an 
identifiable line of differentiation.11 The main core of 
diagnosis of UPS is to exclude other malignant tumors 
that display similar morphological findings such as 
malignant melanomas, sarcomatoid carcinomas, 
anaplastic lymphomas, sarcomatoid mesotheliomas, 
or other sarcomas (e.g., dedifferentiated liposarcoma 
and pleomorphic rhabdomyosarcoma, etc.). Therefore, 
it is a diagnosis of exclusion, which requires careful 
Figure 6. Photomicrographs of the tumor. Immunohistochemistry studies shows no line of differentiation 
(Magnification x10).
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examination of tissue and generous sampling of 
the specimen to stablish a correct diagnosis.12 This 
diagnosis should not be made definitively on a biopsy 
specimen, because the entire mass is not present in 
the biopsy materials. Some authors believe that the 
category of UPS serves primarily as a “wastebasket” 
for a heterogeneous group of unclassifiable neoplasms 
with pleomorphic morphology.13
UPS characteristically shows positive staining 
for histiocytic markers (CD68, α1-antichymotrypsin, 
vimentin), a reason why such tumors were identified 
as “malignant fibrous histiocytoma” (MFH) in the 
past. Staining for TTF-1, S-100 protein, desmin, 
actin, myoglobin, caldesmon, D2-40, and calretinin 
is negative. In some cases, keratin staining may be 
positive, which makes it difficult to differentiate 
sarcomatoid carcinomas (SCs) from UPS. Stronger 
cytokeratin immunoreactivity along with more 
differentiated carcinomatous elements, as well as 
immunoreactivity to other epithelial markers (such as 
P63) can be helpful in the diagnosis of SCs. A wider 
than usual panel of immunohistochemical studies 
is necessary to rule out other neoplasms that can 
resemble UPS including other types of sarcomas, 
sarcomatoid carcinoma, melanoma, or mesothelioma. 
(Table 1). Special staining, electron microscopy, or 
microscopy with ultraviolet surface excitations have 
not shown strong utility in the diagnosis of UPSs.14,15.
Non-specific small droplets of neutral fat and 
PAS-positive, diastase-resistant droplets may be 
seen especially in the giant cells in this tumor, which 
probably reflect a degenerative change.14 Electron 
microscopic features are helpful for evaluation of 
better-differentiated tumors; for example, high aspect 
ratio surface microvilli, perinuclear tonofilaments, and 
hyaluronic acid crystals are seen in more differentiated 
mesotheliomas. However, when the tumor is poorly 
differentiated, the ultrastructural findings are rarely 
helpful.16 The genetic profile of primary pulmonary 
mesenchymal tumors shows complex and nonspecific 
cytogenetic aberrations, similar to their soft tissue 
counterparts. Molecular studies can be helpful to rule 
out other tumors with similar histological findings 
(Table1). Molecular mechanisms responsible for 
primary pulmonary UPS formation and progression 
are unknown.14
It is also important to know that UPS is a relatively 
common soft tissue tumor and most cases of UPS 
found in the lung represent metastasis from an 
extra-pulmonary origin.6 Therefore, a careful clinical 
evaluation to exclude a possible extrapulmonary 
site of origin is necessary before diagnosing primary 
pulmonary UPS (PPUPS).
We provide a brief review of literature on PPUPS 
(previously described as PPMFH) in Table 2. 85 cases 
have been reported in the English literature since 1979, 
Table 2. Review of literature of primary pulmonary undifferentiated pleomorphic sarcoma/primary pulmonary 
fibrous histiocytoma PPUPS/PPMFH. 
# Year Reference Age Sex Location
Size 
(cm)
LN Tx
Survival 
(mos)
F/U
1 1979 Bedrossian et al.4 51 M LLL/RML 3 N L 14 DOD
2 1979 Kern et al.17 53 M RLL 8 N L 12 DOD
3 1980 Chowdhury et al.7 52 F RLL 5 U C 4 DOD
4 1981 Paulsen et al.18 53 F LLL 4 N L 36 DOD
5 1982 Mills et al.19 60 F RLL 10 N L 18 AWD
6 1982 Sriumpai et al.20 41 M RLL 9 U L 18 DOD
7 1983 Misra et al.21 45 M RLL 16 P X 10 DOD
8 1984 Larsen et al.22 75 M RUL 2.5 N R 10 NED
9 1984 Lee et al.23 62 M LLL 6 N L 12 NED
10 1984 Lee et al.23 54 M LUL 7 N C 7 DOD
11 1984 Lee et al.23 69 M RUL 8 N Pn,X 8 NED
AWD = alive with disease; C = chemotherapy; DNED = dead with no evidence of disease; DOD = death of disease; 
DWED = death of non-related cause with evidence of disease; E = endoscopic resection; F/U = follow up; F = female; 
L = lobectomy; LLL = left lower lobe; LN = lymph node; LUL = left upper lobe; M = male; N = negative; NED = no evidence 
of disease; Nt = no treatment; Pn = pneumonectomy; P = positive; R = resection; REB = right endobronchial; RLL = right 
lower lobe; RML = right middle lobe; RUL = right upper lobe; Tx = treatment; U = unavailable data; X = radiotherapy.
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# Year Reference Age Sex Location
Size 
(cm)
LN Tx
Survival 
(mos)
F/U
12 1984 Lee et al.23 62 F LLL 5 N L,X 120 NED
13 1984 Lee et al.23 67 M LUL 4 N L 60 NED
14 1984 Lessel and Erbstösser24 35 F RLL 25 U Nt 12 DOD
15 1984 Silverman and Coalson25 56 M LUL 8 - C 3 AWD
16 1985 Tanino et al.26 75 F LLL 5 + Nt 5 DOD
17 1986 Venn et al.27 32 F RML/RUL U U L 18 NED
18 1986 Venn et al.27 62 M RUL 8 U L 60 NED
19 1986 Venn et al.27 61 F LUL U U Pn 15 DWED
20 1986 Venn et al.27 62 M LUL U U X 2 AWD
21 1987 Hsiu et al.28 71 F RUL 5 N L 10 NED
22 1987 Juettner et al.29 68 M LLL 20 N Nt 12 DOD
23 1987 Juettner et al.29 58 M RLL 5.5 P L 12 DOD
24 1987 Ismailer et al.30 12 F RUL 9 N L 12 AWD
25 1987 Yousem and Hochholzer5 54 F RLL 1.7 N L 108 NED
26 1987 Yousem and Hochholzer5 33 M RUL 3.8 N L 84 NED
27 1987 Yousem and Hochholzer5 59 M RLL 5.9 N L 65 NED
28 1987 Yousem and Hochholzer5 73 F LUL 8.5 P Pn 36 NED
29 1987 Yousem and Hochholzer5 64 M RUL 5 N L,X 16 NED
30 1987 Yousem and Hochholzer5 42 F LLL 3 N L 122 NED
31 1987 Yousem and Hochholzer5 57 F RUL 4 N Pn 1 DNED
32 1987 Yousem and Hochholzer5 80 M LUL 3 N L 1 DNED
33 1987 Yousem and Hochholzer5 74 M LUL U N Nt 2 DOD
34 1987 Yousem and Hochholzer5 18 M RLL 10 N L 1 DOD
35 1987 Yousem and Hochholzer5 46 F RUL 6 P L,X 8 DOD
36 1987 Yousem and Hochholzer5 52 F RLL U N C 9 DOD
37 1987 Yousem and Hochholzer5 52 F LUL 4 P L,C,X 72 DOD
38 1987 Yousem and Hochholzer5 74 F RUL 14 P L 24 DOD
39 1987 Yousem and Hochholzer5 69 F RUL 8 N X 36 DOD
40 1987 Yousem and Hochholzer5 40 F LLL 4 N L,X 24 DOD
AWD = alive with disease; C = chemotherapy; DNED = dead with no evidence of disease; DOD = death of disease; 
DWED = death of non-related cause with evidence of disease; E = endoscopic resection; F/U = follow up; F = female; 
L = lobectomy; LLL = left lower lobe; LN = lymph node; LUL = left upper lobe; M = male; N = negative; NED = no evidence 
of disease; Nt = no treatment; Pn = pneumonectomy; P = positive; R = resection; REB = right endobronchial; RLL = right 
lower lobe; RML = right middle lobe; RUL = right upper lobe; Tx = treatment; U = unavailable data; X = radiotherapy.
Table 2. Continued...
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# Year Reference Age Sex Location
Size 
(cm)
LN Tx
Survival 
(mos)
F/U
41 1987 Yousem and Hochholzer5 74 M RML U N X 8 DOD
42 1987 Yousem and Hochholzer5 19 M LUL U N L,C,X 14 DOD
43 1987 Yousem and Hochholzer5 63 M LLL 7 N Nt 14 DOD
44 1987 Yousem and Hochholzer5 36 M RLL 3 N R 12 DOD
45 1987 Yousem and Hochholzer5 32 M LLL 11 P Pn,C,X 3 DOD
46 1988 Casey and Peddle31 21 M RUL 3 N L 96 NED
47 1988 Casey and Peddle31 46 M LLL 10 N L 8 NED
48 1988 McDonnell et al.32 73 F LLL 6.5 N L 3 DOD
49 1988 Palmer et al.33 62 F RLL U N L 14 DOD
50 1989 White et al.34 55 M RUL U U Nt 4 DOD
51 1990 In et al.35 43 F RLL U U C,X U U
52 1990 Marchán and Pérez36 10 F LLL 5 N L U U
53 1993 Higashiyama et al.37 49 F RLL 6 P Pn U NED
54 1995 Kamath et al.38 56 M RLL 10 U Nt 3 DOD
55 1996 Gómez-Román and Val-Bernal39 61 M RUL 3 U R 9 NED
56 1996 Halyard et al.40 51 F LLL 10 N L,X 60 NED
57 1996 Halyard et al.40 77 M RML 2.2 N L 36 NED
58 1996 Halyard et al.40 40 M LLL 11 P R 6 DOD
59 1996 Halyard et al.40 57 F LUL 7.5 U L 1 DOD
60 1996 Shah et al.41 9 M LUL 6 U L,C,X 36 NED
61 1997 Nistal et al.42 12 F LUL 7 U C,X 5 AWD
62 1997 Barbas et al.43 37 M RML/RLL 10 N Pn 6 DNED
63 2000 Fujita et al.44 65 F LLL 12 U Nt 6 DOD
64 2000 Herrmann et al.45 57 M RUL 13 U L 12 NED
65 2001 Nonaka et al.6 59 M U 4.5 U U U U
66 2002 Alhadab et al.46 56 M LUL/LLL U U Nt 4 DOD
67 2002 Etienne-Mastroianni et al.2 47 M U U U L,X 3 NED
68 2003 Wang et al.47 86 M LLL 15 U Nt 2 DOD
69 2007 Maeda et al.48 62 M LUL 4.5 P L 24 DNED
70 2007 Rzyman et al.49 58 M LUL 4 N Pn 121 NED
71 2007 Rzyman et al.49 61 M RUL 7.5 N L 7 DNED
72 2007 Rzyman et al.49 75 M RUL 8 P Pn 4 DOD
73 2007 Rzyman et al.49 61 F LUL 3 N L 2 DOD
74 2007 Rzyman et al.49 54 M RUL 9 P L 3 DOD
75 2008 Noh et al.50 58 F RUL 5 N L,X 5 NED
76 2010 Maitani et al.51 18 F LUL 2.2 U L 36 NED
AWD = alive with disease; C = chemotherapy; DNED = dead with no evidence of disease; DOD = death of disease; 
DWED = death of non-related cause with evidence of disease; E = endoscopic resection; F/U = follow up; F = female; 
L = lobectomy; LLL = left lower lobe; LN = lymph node; LUL = left upper lobe; M = male; N = negative; NED = no evidence 
of disease; Nt = no treatment; Pn = pneumonectomy; P = positive; R = resection; REB = right endobronchial; RLL = right 
lower lobe; RML = right middle lobe; RUL = right upper lobe; Tx = treatment; U = unavailable data; X = radiotherapy.
Table 2. Continued...
Qorbani A, Nelson SD
9-12Autops Case Rep (São Paulo). 2019 Jul-Sep;9(3):e2019110
including our case. 51 out of 85 case were male and 
35 were female (M:F ratio of 1.45). The patient age 
ranged from 9 to 85 years with a mean age of 54. 
The tumor size ranges from 1.7 to 25 cm, with average 
size of 7.3 cm, and mean survival of 23.73 months. 
Even though PPUPS has a high local recurrences and 
mortality rate, long term survival has been reported in 
some cases, even more than 10 years.5,23,49,52
CONCLUSION
Primary pulmonary undifferentiated pleomorphic 
sarcoma (PPUPS) is an exceptionally rare tumor and 
is essentially a diagnosis of exclusion. The approach 
should be to first establish the absence of any particular 
line of differentiation, which requires proper sampling, 
histological analysis, and immunohistochemistry 
studies. Other ancillary tests such as molecular 
studies and electron microscopy could also possibly 
be helpful. The next step is to exclude any possible 
extrapulmonary origin by clinical examination or by 
other means such as PET-CT scan. PPUPS is a highly 
malignant sarcoma with a poor prognosis, with 
surgery being the primary treatment in most cases. 
Postoperative chemotherapy has also been reported 
to be beneficial in some cases. We report here the 
only case of PPUPS, which was diagnosed in the 
past 17 years at UCLA, after an extensive work up. 
The patient was treated with surgical resection and 
Table 2. Continued...
# Year Reference Age Sex Location
Size 
(cm)
LN Tx
Survival 
(mos)
F/U
77 2010 Tsangaridou et al.52 54 M LLL U N Pn 168 AWD
78 2012 Jeon and Park53 55 M LLL U N Pn,C,X 9 NED
79 2012 Thomas and Koshi54 47 M RUL U P C,X 2 DOD
80 2013 Kim et al.8 61 M REB 3 N E 14 AWD
81 2013 Li et al.55 80 F RUL 8 U Nt 1.5 DOD
82 2014 Liu et al.56 59 F LUL 15.7 N R 8 NED
83 2015 Patel et al.57 86 M RML/RLL 9.6 N L 6 NED
84 2017 Li et al.58 61 M RUL 8 P L U U
85 2019 This study 66 M RLL 15 N L,C 4 NED
AWD = alive with disease; C = chemotherapy; DNED = dead with no evidence of disease; DOD = death of disease; 
DWED = death of non-related cause with evidence of disease; E = endoscopic resection; F/U = follow up; F = female; 
L = lobectomy; LLL = left lower lobe; LN = lymph node; LUL = left upper lobe; M = male; N = negative; NED = no evidence 
of disease; Nt = no treatment; Pn = pneumonectomy; P = positive; R = resection; REB = right endobronchial; RLL = right 
lower lobe; RML = right middle lobe; RUL = right upper lobe; Tx = treatment; U = unavailable data; X = radiotherapy.
post-operative chemotherapy. With 4 months follow 
up, there is no evidence of local recurrence or distant 
metastasis.
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